AU2019395255B2 - Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof - Google Patents

Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof Download PDF

Info

Publication number
AU2019395255B2
AU2019395255B2 AU2019395255A AU2019395255A AU2019395255B2 AU 2019395255 B2 AU2019395255 B2 AU 2019395255B2 AU 2019395255 A AU2019395255 A AU 2019395255A AU 2019395255 A AU2019395255 A AU 2019395255A AU 2019395255 B2 AU2019395255 B2 AU 2019395255B2
Authority
AU
Australia
Prior art keywords
certain embodiments
optionally substituted
hydrogen
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019395255A
Other languages
English (en)
Other versions
AU2019395255A1 (en
Inventor
Yang Gao
Nathanael S. Gray
Yao Liu
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2019395255A1 publication Critical patent/AU2019395255A1/en
Application granted granted Critical
Publication of AU2019395255B2 publication Critical patent/AU2019395255B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019395255A 2018-12-14 2019-12-13 Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof Active AU2019395255B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780066P 2018-12-14 2018-12-14
US62/780,066 2018-12-14
PCT/US2019/066201 WO2020123925A1 (en) 2018-12-14 2019-12-13 Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof

Publications (2)

Publication Number Publication Date
AU2019395255A1 AU2019395255A1 (en) 2021-05-06
AU2019395255B2 true AU2019395255B2 (en) 2025-02-27

Family

ID=71077020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019395255A Active AU2019395255B2 (en) 2018-12-14 2019-12-13 Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof

Country Status (7)

Country Link
US (1) US20220073512A1 (https=)
EP (1) EP3893879A4 (https=)
JP (1) JP7642540B2 (https=)
CN (1) CN113164477A (https=)
AU (1) AU2019395255B2 (https=)
CA (1) CA3115126A1 (https=)
WO (1) WO2020123925A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2017363307B2 (en) * 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA3147422A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN120661695B (zh) * 2025-06-20 2026-03-20 山东大学齐鲁第二医院 联合上调snrk基因与gsk3b基因表达水平在制备抗非小细胞肺癌药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074986A1 (en) * 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US20160264554A1 (en) * 2013-10-18 2016-09-15 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
BR112013011520A2 (pt) * 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074986A1 (en) * 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US20160264554A1 (en) * 2013-10-18 2016-09-15 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)

Also Published As

Publication number Publication date
AU2019395255A1 (en) 2021-05-06
JP2022513846A (ja) 2022-02-09
US20220073512A1 (en) 2022-03-10
WO2020123925A1 (en) 2020-06-18
EP3893879A4 (en) 2022-08-17
CA3115126A1 (en) 2020-06-18
CN113164477A (zh) 2021-07-23
JP7642540B2 (ja) 2025-03-10
EP3893879A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
AU2019395255B2 (en) Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
AU2016283105C1 (en) 4,6-pyrimidinylene derivatives and uses thereof
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
AU2016319116B2 (en) Cyano thienotriazolodiazepines and uses thereof
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
AU2015371251A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2020319005B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2016210291A1 (en) Fused bicyclic pyrimidine derivatives and uses thereof
CA2988330C (en) 4,6-pyrimidinylene derivatives and uses thereof
CA2972239C (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1254654B (en) 4,6-pyrimidinylene derivatives and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)